Michael Ackermann is CEO of medical device company Presidio Medical, Inc., Chairman of Oyster Point Pharmaceuticals and Chairman of Tarsus Pharmaceuticals, Inc. Michael is also teaching faculty at Stanford University’s Biodesign program. Prior, Michael served as Vice President, Neurostimulation for Allergan, plc after serving as CEO of Oculeve, Inc., which was acquired by Allergan in August 2015. He received a bachelor’s degree in biomedical engineering from Vanderbilt University, M.S. and Ph.D. degrees in biomedical engineering from Case Western Reserve University is a graduate of the Stanford University Biodesign Fellowship, and Vision Research Fellowship at Stanford.